

Report prepared for Physician: [REDACTED]
 Practice Group: [REDACTED]
 PFP Group: [REDACTED]

	Your Practice Group Score						Comparison Scores			
	# Members Met Criteria	# Members Eligible	Score	Target	Favorable/Unfavorable		Physician	PFP Group	Plan	
Preventive Health										
Mammography	574	676	85%	80%	+ 5	▲	85%	79%	80%	
Cervical Cancer Screens	760	813	93%	88%	+ 5	▲	95%	90%	90%	
Chlamydia Screenings	29	122	24%	46%	(22)	▼	6%	24%	31%	
Colorectal Cancer Screens	561	824	68%	76%	(8)	▼	77%	65%	63%	
Childhood Immunizations (w/pneum. conj.)	77	91	85%	87%	(2)	▼	88%	74%	80%	
Adolescent Immunizations	83	84	99%	81%	+ 18	▲	100%	96%	83%	
Well Child Visits Age 3-6	283	371	76%	83%	(7)	▼	81%	75%	68%	
Adolescent Well Care Visits	284	686	41%	55%	(14)	▼	40%	38%	37%	
Disease Management										
Diabetes Care: Controlled HbA1c	75	140	54%	60%	(6)	▼	61%	44%	39%	
Diabetes Care: Controlled LDL-C	81	140	58%	60%	(2)	▼	61%	47%	41%	
Diabetes Care: Annual Retinal Eye Exam	126	140	90%	90%	0	▲	100%	79%	74%	
Diabetes Care: Monitoring for Nephropathy	129	140	92%	90%	+ 2	▲	83%	81%	85%	
Asthma Medication Management	77	140	55%	60%	(5)	▼	92%	86%	78%	
Depression Optimal Contacts	3	140	2%	60%	(57)	▼	25%	15%	17%	
Appropriate Treatment for Children with URI	40	140	29%	60%	(31)	▼	100%	92%	86%	
Appropriate Treatment for Children with Pharyngitis	78	140	56%	60%	(4)	▼	91%	88%	77%	
Use of Imaging Studies for Low Back Pain	30	140	21%	60%	(39)	▼	83%	72%	73%	
Appropriate Antibiotic Treatment of Adults with Acute Bronchitis	27	140	19%	60%	(41)	▼	50%	70%	71%	
Use of Spirometry Testing in the Assessment and Diagnosis of COPD	3	8	38%	40%	(2)	▼	0%	31%	36%	
Initiation of AOD Dependence Treatment	14	31	45%	59%	(14)	▼	60%	44%	44%	
Engagement of AOD Treatment	3	31	10%	24%	(14)	▼	20%	11%	15%	
Persistence of ACE/ARB-Statin Therapy	45	109	41%	60%	(19)	▼	46%	38%	31%	

PERSISTANCE OF ACEI/ARB and STATIN THERAPY MEASURE

This measure is defined as the percent of patients 55 years and older diagnosed with diabetes, IVD (CAD, PVD, Stroke) or CHF who have obtained a 270 day supply of both an ACEI/ARB and Statin during the recent rolling 12 month period.

This report provides information on quality measures over a rolling period of time. It is not intended to predict your results for the current year Physician Incentive Program.

Emerging evidence shows that ACE/ARB and statin (AAS) use in combination reduces morbidity and mortality for patients with diabetes, CHF, and peripheral vascular disease. The combination of AAS has been shown to reduce cardiovascular events by as much as 50% over 8 years for these patients when they are over 55 years of age. Currently, only 31% of Priority Health members are taking these medications 9 out of 12 months. We want to reduce cardiovascular morbidity for those patients at risk by improving adherence to this evidenced based practice to 60%. To improve adherence please prescribe an ACEI or ARB, and a statin and closely monitor those patients at risk.